Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quintiles Acquires Outcome Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News

Quintiles Acquires Outcome Sciences

Adds Late Phase Offerings

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Quintiles has acquired Outcome Sciences, Inc., a privately held outcomes research firm headquartered in Cambridge, MA. The acquisition adds late phase research, offering global reach, dedicated resources and specialization.

Outcome is a provider of observational research services encompassing registries, post-approval research and quality improvement initiatives across biopharmaceutical, medical device, government and providers. Outcome’s programs across more than 40 therapeutic areas include thousands of sites and millions of patients in more than 80 countries.

“This acquisition underscores Quintiles’ commitment to delivering efficient, insightful late phase solutions to help customers show the value of their products to patients, providers and payers,” said Quintiles president and chief operating officer, John Ratliff. “The Phase IIIb/IV market is forecast to reach more than $4 billion by 2015, up significantly from 2010. We estimate that observational research accounts for about 30% of that market, and Outcome is the notable leader in it. With this acquisition, no other biopharmaceutical services company can match Quintiles’ level of late phase science and strategy, global reach and service specialization.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics